Santarus & VeroScience Announce Publication of AACE Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for ...
March 06 2013 - 7:00AM
Business Wire
Santarus, Inc. (NASDAQ: SNTS) and VeroScience, LLC today
announced publication of a review article and recommendations of an
American Association of Clinical Endocrinologists (AACE) expert
panel on the role of bromocriptine-QR in the management of type 2
diabetes. The panel concluded that treatment with CYCLOSET®
(bromocriptine mesylate), also referred to as bromocriptine-QR, may
be useful in the treatment of patients with type 2 diabetes, both
early and late in the life cycle of the disease, and especially for
patients with a history of cardiovascular disease or who have
significant risk factors for cardiovascular disease. The article,
titled The Role of Bromocriptine-QR in the Management of Type 2
Diabetes Expert Panel Recommendations will appear in print form in
the January/February issue of Endocrine Practice, a peer-reviewed
medical journal published by AACE, and can be found in the online
edition of the journal at
http://aace.metapress.com/home/main.mpx.
The expert panel also made the following observations and
recommendations:
- CYCLOSET has a novel mechanism of
action that appears to involve enhancement of morning central
nervous system dopaminergic activity, which is reduced in obese
individuals with type 2 diabetes. This improvement can potentially
lead to improved insulin sensitivity and reduced hepatic glucose
output.
- Adjunctive administration of CYCLOSET
in the dosing range of 1.6 mg/day to 4.8 mg/day may result in a
mean reduction in A1c levels of 0.69% (95% Confidence Interval:
0.97%, 0.41%).
- A 24-week completer analysis performed
among efficacy subgroups of patients from the CYCLOSET safety study
stratified based on the patient’s baseline A1c levels (≥7.5 to
Santarus (NASDAQ:SNTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Santarus (NASDAQ:SNTS)
Historical Stock Chart
From Jul 2023 to Jul 2024